The FDA was expected to decide on the application of sotorasib and panitumumab for the treatment of metastatic colorectal ...

The regulator has delayed its respective decision dates on whether to grant full approval to Amgen’s Lumakras in metastatic ...

The FDA is looking at four events for the remainder of October, one of which is an advisory committee meeting for a dual SGLT ...

Lumakras was cleared by the FDA in May 2021 for KRAS G12C-mutated NSCLC patients who have received at least one prior systemic therapy, marking the culmination of a decades-long effort to bring a ...

Amgen has made progress with its plans to expand the use of its first-in-class KRAS inhibitor Lumakras, reporting encouraging results when the drug is used alongside its EGFR drug Vectibix in ...

LUMAKRAS Dosing Confirmed at 960 mg Once-Daily for Patients With KRAS G12C-Mutated NSCLC Under Accelerated Approval Amgen (NASDAQ:AMGN) announced today that the U.S. Food and Drug Administration (FDA) ...

Amgen will need to run another confirmatory study to win full FDA approval of its lung-cancer drug Lumakras. Amgen says the FDA, which granted conditional approval to the drug in 2021, has turned ...

NEW YORK – The first data from a trial of Amgen's KRAS inhibitor Lumakras (sotorasib) combined with its anti-EGFR monoclonal antibody Vectibix (panitumumab) and chemo in first-line KRAS G12C-mutant ...

HAIKOU, August 24. /TASS/. An innovative American drug Lumakras (also known as Sotorasib) for lung cancer and other types of cancer may soon become available at Hainan Lecheng Medical Cluster ...

Sales of some key brands like Otezla and Lumakras are below expectations. However, revenues from key older medicines like ...

Some of its most recent brand-new launches, especially the cancer drug Lumakras, have made paltry (at best) contributions to its top line, while some of its legacy products are racking up ...